Healthpeak Properties Declares Monthly Common Stock Cash Dividends for the Second Quarter of 2026
Get Alerts DOC Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 6.1%
EPS Growth %: -20.0%
Join SI Premium – FREE
DENVER--(BUSINESS WIRE)-- Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, announced that on April 6, 2026, its Board of Directors declared a monthly common stock cash dividend of $0.10167 per share for the second quarter of 2026, payable on the payment dates set forth in the table below to stockholders of record as of the close of business on the corresponding record date in the table below. The monthly dividend reflects an annualized dividend amount of $1.22 per share of common stock.
Record Date |
Payment Date |
Amount |
Friday, April 17, 2026 |
Thursday, April 30, 2026 |
$0.10167 per common share |
Monday, May 18, 2026 |
Friday, May 29, 2026 |
$0.10167 per common share |
Monday, June 15, 2026 |
Friday, June 26, 2026 |
$0.10167 per common share |
ABOUT HEALTHPEAK PROPERTIES
Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery. For more information regarding Healthpeak, visit www.healthpeak.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260406365686/en/
Andrew Johns, CFA
Senior Vice President – Finance and Investor Relations
720-428-5050
Source: Healthpeak Properties, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CroíValve Announces Expansion of Series B Financing with $27 Million Additional Capital to Fund DUO Adapt in an Enlarged TANDEM II Study
- ustwo and University of Bristol Launch PRISM, a New Open-Source Tool That Helps Developers Understand the Carbon Impact of AI Usage During Development
- Vividion Therapeutics Doses First Patient in Phase Ib Combination Study of WRN Inhibitor VVD-214 in Patients with Advanced Colorectal Cancer
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share